References
  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359-86.
  2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156–1161.
  3. Djavan B, Zlotta A, Kratzik C. et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology, 54: 517-522, 1999.
  4. Yoshida K, Honda M, Sumi S, et al. Levels of free prostate-specificantigen (PSA) can be selectively measured by heat treatment of serum: free/ total-PSA ratios improve detection of prostate carcinoma. Clin Chim Acta. 1999;280:195–203.
  5. Catalona WJ, Southwick PC, Slawin KM, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 56:255-260, 2000.
  6. Albertsen PC , Hanley JA , Fine J . 20-year outcomes following conservative management of clinically localized prostate cancer .JAMA 2005 ; 293 : 2095 – 101.
  7. Lu-Yao GL , Albertsen PC , Moore DF et al . Outcomes of localized prostate cancer following conservative management . JAMA 2009 ; 3 02 : 1202 – 9.
  8. Ceylan C, Gazel E, Keleş İ, Doluoǧlu Ö, Yıǧman M. Can the free/total PSA ratio predict the Gleason score before prostate biopsy? Curr Urol. 2016;9:24–7.
  9. Liu J, Wang ZQ, Li M, Zhou MY, Yu YF, Zhan WW. Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4-10 ng ml(-1)). Asian J Androl. 2020;22(2):213-6.
  10. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016;40:244– 52.
  11. Salami SS, Palapattu GS, Partin AW, Morgan TM. Campbell Walsh Wein Urology, 12th Edition.Elsevier, 2020. Section XIV Prostate; 108. Prostate cancer biomarkers.
  12. Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 2018;362:k3519.
  13. Omri N, Kamil M, Alexander K, et al. Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume. The Prostate. 2020;1‐6.
  14. Han C, Liu S, Qin XB, Ma S, Zhu LN, Wang XY. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI. Diagn Interv Imaging 2020;101:235-244.
  15. Wei C, Chen T, Zhang Y, et al. Biparametric prostate MRI and clinical indicators predict clinically significant prostate cancer in men with “gray zone” PSA levels. European Journal of Radiology 127 (2020) 108977
  16. Ha YS, Yu J, Salmasi AH, Patel N, Parihar J, Singer EA, et al. Prostate-specific antigen density toward a better cutoff to identify better candidates for active surveillance.  Urology 2014;  84: 365–71.
  17. Corcoran NM, Casey RG, Hong MKH et al: The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. BJU Int 2012; 110: 36-42.